Lead Product(s) : M041
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Evidence that M041, phosphorylated alpha-N-acetylglucosaminidase, has improved trafficking and binding to M6P receptors. M041 has markedly improved cellular uptake in patient fibroblasts when compared to wild type alpha-N-acetylglucosaminidase.
Brand Name : M041
Molecule Type : Large molecule
Upfront Cash : Not Applicable
February 02, 2022
Lead Product(s) : M041
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : M041
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
M6P Therapeutics Presented Data on M041
Details : As the study suggests, M6PT’s M041 recombinant enzyme therapy (NAGLUM6P) employs an efficient and well-trafficked lysosomal enzyme as the key to developing a potentially effective therapy to treat this rare pediatric disorder.
Brand Name : M041
Molecule Type : Large molecule
Upfront Cash : Not Applicable
July 28, 2021
Lead Product(s) : M041
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?